Vitrimark is developing new biomarkers for use in the drug development process. Identification of disease-specific biomarkers, those measurable characteristics that act as indicators of pharmaceutical responses to therapeutic interventions, reduce the cost associated with drug development by identifying failures at an early stage and identifying niche patient populations with high drug efficacy.
Vitrimark exploits the unique advantages provided by nanoscale cryoimaging of biofluids to identify ultrastructural biomarkers. Current methods for determining biomarkers involve functional assays. The fundamental premise of Vitrimark’s patent-pending technology is that ultrastructural changes precede functional changes and thus allow earlier detection potential. The company’s initial focus is on developing structural biomarkers for prostate cancer, prediabetes, and diabetes.
© 2017 Slater Technology Fund | Contact